Larimar Therapeutics, Inc. (LRMR) Stock Forecast
LRMR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.82 / 5 from 11 analysts
- Price target
- $14.40 average of analyst targets
- Upside to target
- +625.4% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.35
- 52-week range
- $1.99 – $5.95
LRMR analyst ratings
11 analystsNumber of analysts at each rating.
LRMR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LRMR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.37 | −$0.31 | −$0.61 | +42.8% | 7 |
| Current fiscal year (2026) | −$1.35 | −$1.49 | −$1.14 | −$2.27 | +40.5% | 7 |
| Next fiscal year (2027) | −$1.06 | −$1.49 | −$0.29 | −$1.35 | +21.5% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LRMR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 11 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 11 |
| Next fiscal year (2027) | $41.7M | $4.6M | $164.5M | 0.0% | 11 |
LRMR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LRMR revenue: reported and forecast
LRMR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.42 | −$0.42 | −$0.35 | −$0.35 | −$0.35 | −17.2% | 6 up · 0 down |
| Current fiscal year (2026) | −$1.61 | −$1.61 | −$1.35 | −$1.35 | −$1.35 | −16.0% | 6 up · 0 down |
| Next fiscal year (2027) | −$1.16 | −$1.18 | −$1.06 | −$1.06 | −$1.06 | −8.7% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LRMR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LRMR beat in 5 of 12.
What analysts expect from LRMR
11 analysts cover Larimar Therapeutics; their consensus rating is strong buy (4.82 on a 1–5 scale, where 5 is a strong buy). The average price target is $14.40, 625.4% above the latest close of $1.99. Analysts expect earnings of −$1.35 per share for 2026, +40.5% from a year earlier. For 2027 the average estimate is −$1.06 per share on revenue of $41.7 million. Larimar Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: LRMR income statement, LRMR key metrics, LRMR chart. See the LRMR stock overview for the latest quote and news.
LRMR forecast FAQ
What is Larimar Therapeutics's price target?
The average analyst price target for Larimar Therapeutics is $14.40, 625.4% above the latest close of $1.99.
Is Larimar Therapeutics a buy, hold or sell?
Of 11 analysts covering Larimar Therapeutics, 9 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Larimar Therapeutics's EPS forecast?
Analysts forecast −$1.35 per share for 2026 (range −$1.49 to −$1.14); for 2027 the estimate is −$1.06.
When does Larimar Therapeutics report earnings?
Larimar Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.35.
Does Larimar Therapeutics usually beat earnings estimates?
Larimar Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.